Does the media prefer BEAM or ZVRA?

In the previous week, Beam Therapeutics had 5 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 2 mentions for Zevra Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat Zevra Therapeutics' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ZVRA or ADPT?

In the previous week, Adaptive Biotechnologies had 13 more articles in the media than Zevra Therapeutics. MarketBeat recorded 15 mentions for Adaptive Biotechnologies and 2 mentions for Zevra Therapeutics. Adaptive Biotechnologies' average media sentiment score of 0.58 beat Zevra Therapeutics' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZVRA or DYN?

In the previous week, Dyne Therapeutics had 12 more articles in the media than Zevra Therapeutics. MarketBeat recorded 14 mentions for Dyne Therapeutics and 2 mentions for Zevra Therapeutics. Dyne Therapeutics' average media sentiment score of 0.61 beat Zevra Therapeutics' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZVRA or GMTX?

Zevra Therapeutics currently has a consensus price target of $29.29, suggesting a potential upside of 125.27%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to RCUS or ZVRA?

In the previous week, Zevra Therapeutics had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 2 mentions for Zevra Therapeutics and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Zevra Therapeutics' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zevra Therapeutics (ZVRA) Competitors

$13.00 +0.35 (+2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$12.89 -0.11 (-0.85%)

As of 07:59 PM Eastern

Compare

ZVRA vs. BEAM, ADPT, DYN, GMTX, and RCUS

Should you buy Zevra Therapeutics stock or one of its competitors? MarketBeat compares Zevra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zevra Therapeutics include Beam Therapeutics (BEAM), Adaptive Biotechnologies (ADPT), Dyne Therapeutics (DYN), Gemini Therapeutics (GMTX), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does Zevra Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zevra Therapeutics has a net margin of 101.58% compared to Beam Therapeutics' net margin of -39.66%. Zevra Therapeutics' return on equity of 51.49% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Zevra Therapeutics	101.58%	51.49%	28.86%

Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Beam Therapeutics currently has a consensus price target of $46.83, indicating a potential upside of 41.06%. Zevra Therapeutics has a consensus price target of $29.29, indicating a potential upside of 125.27%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Beam Therapeutics had 5 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 2 mentions for Zevra Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat Zevra Therapeutics' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	24.44	-$79.99M	-$0.68	N/A
Zevra Therapeutics	$122.29M	6.28	$83.23M	$1.99	6.53

Summary

Beam Therapeutics beats Zevra Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Zevra Therapeutics compare to Adaptive Biotechnologies?

Zevra Therapeutics (NASDAQ:ZVRA) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Zevra Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.15, indicating that its share price is 115% more volatile than the broader market.

Zevra Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	6.28	$83.23M	$1.99	6.53
Adaptive Biotechnologies	$276.98M	9.96	-$59.50M	-$0.33	N/A

Zevra Therapeutics has a net margin of 101.58% compared to Adaptive Biotechnologies' net margin of -16.82%. Zevra Therapeutics' return on equity of 51.49% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Zevra Therapeutics presently has a consensus target price of $29.29, suggesting a potential upside of 125.27%. Adaptive Biotechnologies has a consensus target price of $20.33, suggesting a potential upside of 18.01%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Adaptive Biotechnologies had 13 more articles in the media than Zevra Therapeutics. MarketBeat recorded 15 mentions for Adaptive Biotechnologies and 2 mentions for Zevra Therapeutics. Adaptive Biotechnologies' average media sentiment score of 0.58 beat Zevra Therapeutics' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zevra Therapeutics beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Dyne Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

In the previous week, Dyne Therapeutics had 12 more articles in the media than Zevra Therapeutics. MarketBeat recorded 14 mentions for Dyne Therapeutics and 2 mentions for Zevra Therapeutics. Dyne Therapeutics' average media sentiment score of 0.61 beat Zevra Therapeutics' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics currently has a consensus target price of $29.29, suggesting a potential upside of 125.27%. Dyne Therapeutics has a consensus target price of $33.85, suggesting a potential upside of 67.06%. Given Zevra Therapeutics' higher probable upside, research analysts plainly believe Zevra Therapeutics is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93

Zevra Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	6.28	$83.23M	$1.99	6.53
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Zevra Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Zevra Therapeutics has a net margin of 101.58% compared to Dyne Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Summary

Zevra Therapeutics and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Gemini Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Zevra Therapeutics had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Zevra Therapeutics and 0 mentions for Gemini Therapeutics. Zevra Therapeutics' average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Gemini Therapeutics	Neutral

Zevra Therapeutics has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	6.28	$83.23M	$1.99	6.53
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Zevra Therapeutics currently has a consensus price target of $29.29, suggesting a potential upside of 125.27%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Zevra Therapeutics has a net margin of 101.58% compared to Gemini Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Gemini Therapeutics	N/A	-38.78%	-35.88%

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zevra Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Summary

Zevra Therapeutics beats Gemini Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Zevra Therapeutics compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Zevra Therapeutics has a net margin of 101.58% compared to Arcus Biosciences' net margin of -156.36%. Zevra Therapeutics' return on equity of 51.49% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Zevra Therapeutics	101.58%	51.49%	28.86%

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arcus Biosciences presently has a consensus target price of $35.10, suggesting a potential upside of 24.64%. Zevra Therapeutics has a consensus target price of $29.29, suggesting a potential upside of 125.27%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Zevra Therapeutics had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 2 mentions for Zevra Therapeutics and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Zevra Therapeutics' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	14.34	-$353M	-$3.18	N/A
Zevra Therapeutics	$122.29M	6.28	$83.23M	$1.99	6.53

Arcus Biosciences has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

Zevra Therapeutics beats Arcus Biosciences on 10 of the 15 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVRA vs. The Competition

Export

Metric	Zevra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$747.81M	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	6.53	18.43	24.92	23.98
Price / Sales	6.28	336.82	529.01	109.54
Price / Cash	13.37	56.31	44.82	54.51
Price / Book	4.73	4.11	10.79	6.50
Net Income	$83.23M	$64.45M	$3.56B	$336.88M
7 Day Performance	2.77%	2.24%	1.67%	-0.22%
1 Month Performance	29.61%	1.04%	0.43%	0.77%
1 Year Performance	44.44%	30.05%	32.84%	31.57%

Zevra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVRA Zevra Therapeutics	3.8989 of 5 stars	$13.00 +2.8%	$29.29 +125.3%	+39.9%	$747.81M	$122.29M	6.53	20	Analyst Forecast
BEAM Beam Therapeutics	3.2842 of 5 stars	$29.03 -1.3%	$46.83 +61.3%	+112.0%	$3.03B	$139.74M	N/A	510
ADPT Adaptive Biotechnologies	3.5134 of 5 stars	$17.60 -6.0%	$19.57 +11.2%	+67.3%	$3.00B	$276.98M	N/A	790
DYN Dyne Therapeutics	2.6044 of 5 stars	$18.19 +1.3%	$35.00 +92.4%	+102.2%	$2.97B	N/A	N/A	100	Analyst Upgrade Gap Down
GMTX Gemini Therapeutics	N/A	$67.99 -0.1%	N/A	+37.2%	$2.95B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVRA) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. BEAM, ADPT, DYN, GMTX, and RCUS

How does Zevra Therapeutics compare to Beam Therapeutics?

Summary

How does Zevra Therapeutics compare to Adaptive Biotechnologies?

Summary

How does Zevra Therapeutics compare to Dyne Therapeutics?

Summary

How does Zevra Therapeutics compare to Gemini Therapeutics?

Summary

How does Zevra Therapeutics compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. BEAM, ADPT, DYN, GMTX, and RCUS

How does Zevra Therapeutics compare to Beam Therapeutics?

Do institutionals & insiders hold more shares of BEAM or ZVRA?

Is BEAM or ZVRA more profitable?

Which has more risk and volatility, BEAM or ZVRA?

Do analysts prefer BEAM or ZVRA?

Does the media prefer BEAM or ZVRA?

Which has higher valuation & earnings, BEAM or ZVRA?

Summary

How does Zevra Therapeutics compare to Adaptive Biotechnologies?

Which has more risk & volatility, ZVRA or ADPT?

Which has preferable valuation & earnings, ZVRA or ADPT?

Is ZVRA or ADPT more profitable?

Do institutionals and insiders have more ownership in ZVRA or ADPT?

Do analysts prefer ZVRA or ADPT?

Does the media prefer ZVRA or ADPT?

Summary

How does Zevra Therapeutics compare to Dyne Therapeutics?

Does the media favor ZVRA or DYN?

Do analysts recommend ZVRA or DYN?

Which has higher earnings & valuation, ZVRA or DYN?

Do insiders & institutionals believe in ZVRA or DYN?

Which has more risk and volatility, ZVRA or DYN?

Is ZVRA or DYN more profitable?

Summary

How does Zevra Therapeutics compare to Gemini Therapeutics?

Does the media favor ZVRA or GMTX?

Which has stronger valuation and earnings, ZVRA or GMTX?

Do analysts rate ZVRA or GMTX?

Is ZVRA or GMTX more profitable?

Do insiders & institutionals believe in ZVRA or GMTX?

Which has more risk and volatility, ZVRA or GMTX?

Summary

How does Zevra Therapeutics compare to Arcus Biosciences?

Is RCUS or ZVRA more profitable?

Do institutionals and insiders believe in RCUS or ZVRA?

Do analysts prefer RCUS or ZVRA?

Does the media refer more to RCUS or ZVRA?

Which has higher valuation and earnings, RCUS or ZVRA?

Which has more volatility & risk, RCUS or ZVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools